Shares of clinical-stage biotechnology company Vaxart, Inc. (VXRT) are surging more than 20% Monday morning after the company announced that it has received clearance from the FDA to start human trials of its Covid-19 vaccine candidate.
The FDA has completed its review of the Company’s Investigational New Drug (IND) application for its Phase 1 clinical trial evaluating its oral COVID-19 vaccine candidate, the company said.
The stock is currently trading at $6.45. It has traded in the range of $0.25- $17.49 in the past 52 weeks.
Source: Read Full Article